CHICAGO (AP) — A drugmaker is clashing with pediatricians over new recommendations to limit use of a costly medicine for preventing serious lung problems in preemies and other high-risk children. The dispute involves new American Academy of Pediatrics guidelines that say medical evidence shows the drug has limited benefits.Read more on NewsOK.com